SCHEMBL95515

SCHEMBL95515

[2H]C([2H])(c1ccc(C)cc1)n1c(CN2CCCC2)nc2ccccc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.63
CYP2D6 P10635 2/20 0.63
CYP2C9 P11712 2/20 0.63
CYP2C19 P33261 2/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
ALDH1A1 P00352 1/20 0.63
HIF1A Q16665 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
NR1I2 O75469 1/20 0.62
ABCB11 O95342 1/20 0.62
LMNA P02545 1/20 0.62
ESR1 P03372 1/20 0.62
PGR P06401 1/20 0.62
CYP3A4 P08684 1/20 0.62
PKM P14618 1/20 0.62
TSHR P16473 1/20 0.62
ADRA2B P18089 1/20 0.62
HTR2A P28223 1/20 0.62
ADRA1A P35348 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94946 0.93 MEN1 (0.53) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL94944 0.91 MEN1 (0.51) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL13144806 0.89 CYP1A2 (0.80) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL94945 0.88 MEN1 (0.52) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
Clemizole SCHEMBL95037 0.88 HIF1A (0.81) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL94942 0.85 MEN1 (0.63) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL94953 0.83 MEN1 (0.52) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL95517 0.82 MEN1 (0.66) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL95444 0.80 MEN1 (0.64) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
Clemizole SCHEMBL95696 0.79 HIF1A (0.67) CYP1A2CYP2D6CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058085-A1 Deuterium Modified Benzimidazoles CONCERT PHARMACEUTICALS, INC. 2012-03-08 US disclosed
US-20100284970-A1 BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN AUSPEX PHARMACEUTICALS, INC. (US) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058085-A1 Deuterium Modified Benzimidazoles POLRMT, EIF2AK2, DUT CYP1A2 936/4885CYP2D6 724/4885CYP2C9 1715/4885
US-20100284970-A1 BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN HRH4, H1-4, HRH3 CYP1A2 748/4885CYP2D6 641/4885CYP2C9 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.